ZoomMed Inc. has sold certain assets to TELUS Health
TELUS Health, Canada’s largest Electronic Medical Records (EMR) provider and a leader in the Canadian claims and benefits management sector, is adding important new functionality to its existing health technology portfolio through its acquisition of an interest in the underlying technology of the ZRx Prescriber from Quebec-based ZoomMed Inc. Financial details have not been disclosed.
ZoomMed Inc. is a publicly traded company (TSXV: ZMD) that builds and operates a clinical information exchange platform between physicians, pharmacists and the various other stakeholders of the Health sector with whom they interact. The company has the largest private network of electronic prescriptions and drug information system in Canada.
TELUS Health is a leader in telehomecare, electronic medical and health records, consumer health, benefits management and pharmacy management. TELUS Health solutions give health authorities, providers, physicians, patients and consumers the power to turn information into better health outcomes. It is an operating subsidiary of TELUS (TSX: T), one of Canada’s largest telecommunication companies.
“This acquisition builds upon our EMR leadership position and claims and benefits expertise, and allows us to have a more direct and positive impact on the patient experience, which ultimately leads to better health outcomes for Canadians,” said Paul Lepage, President of TELUS Health.
Oaklins' team in Montreal advised the seller in this transaction.
Contacter l'équipe de la transaction
Associé directeurMontréal, Canada
Oaklins E. Canada
Chef de la directionMontréal, Canada
Oaklins E. Canada
Narva clinics has been acquired by Narva Åderbråckscenter AB
The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.En apprendre plus
NS PARTNERS CO., LTD. has been acquired by JMDC Inc.
Noritsu Koki Co., Ltd has sold NS PARTNERS CO., LTD. to JMDC Inc.En apprendre plus
Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.En apprendre plus